If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
![]() Fundamental & Clinical PharmacologyVolume 20 Issue 1, Pages 9 - 19 Published Online: 22 Dec 2005 Journal compilation © 2010 Société Française de Pharmacologie et de Thérapeutique Published on behalf of the Société Française de Pharmacologie et de Thérapeutique
Abstract | References | Full Text: HTML, PDF (Size: 149K) | Related Articles | Citation Tracking ORIGINAL ARTICLE Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma Copyright 2005 Blackwell Publishing Ltd KEYWORDS adenosine • adenosine receptors • asthma • bronchoconstriction • new therapies Abstract
Interest in the role of adenosine in asthma has escalated considerably since the early observation of its powerful bronchoconstrictor effects in asthmatic but not normal airways. A growing body of evidence has emerged in support of a proinflammatory and immunomodulatory role for the purine nucleoside adenosine in the pathogenic mechanisms of chronic inflammatory disorders of the airways such as asthma. The fact that adenosine enhances mast cell allergen-dependent activation, that elevated levels of adenosine are present in chronically inflamed airways, and that adenosine given by inhalation cause dose-dependent bronchoconstriction in subjects with asthma emphasizes the importance of adenosine in the initiation, persistence and progression of these common inflammatory disorders of the airways. These distinctive features of adenosine have been recently exploited in the clinical and research setting to identify innovative diagnostic applications for asthma. In addition, because adenosine exerts its multiple biological activities by interacting with four adenosine receptor subtypes, selective activation or blockade of these receptors may lead to the development of novel therapies for asthma. Received 1 July 2005; revised 16 September 2005; accepted 28 October 2005 |